Iron-chelating effect of silymarin in patients with -thalassemia major: A crossover randomised control trial

This study aimed to determine the potential iron-chelating effects of silymarin in patients with -thalassemia major receiving standard iron-chelation therapy. We evaluated whether addition of silymarin to standard iron-chelation therapy could improve iron burden markers and liver and cardiac function in these patients, via a placebo-controlled, crossover clinical study. Silymarin (140mg) or placebo were administered thrice daily to all patients (n=82) for 12weeks, and after a 2-week washout period, patients were crossed over to the other groups. Silymarin efficacy was assessed by measuring serum iron level, ferritin level, total iron-binding capacity and liver and cardiac function on magnetic resonance imaging. Silymarin treatment resulted in a negative change in the serum iron and ferritin levels and a positive change in the total iron-binding capacity levels (treatment effect, p<.001, p=.06, and p=.05, respectively). Silymarin treatment led to positive changes in cardiac and liver function in both treatment sequences of study; however, this was not statistically significant. There was a negative change in liver iron concentration in both treatment sequences (treatment effect, p=.02). In conclusion, combined iron-chelation and silymarin therapy was effective for improving the iron-burden status in patients with -thalassemia major.